EP1140792A1 - Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4 - Google Patents

Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4

Info

Publication number
EP1140792A1
EP1140792A1 EP99967265A EP99967265A EP1140792A1 EP 1140792 A1 EP1140792 A1 EP 1140792A1 EP 99967265 A EP99967265 A EP 99967265A EP 99967265 A EP99967265 A EP 99967265A EP 1140792 A1 EP1140792 A1 EP 1140792A1
Authority
EP
European Patent Office
Prior art keywords
dioxo
compound
cyclobut
pharmaceutical salt
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99967265A
Other languages
German (de)
English (en)
Inventor
Louis John Lombardo
Joan E. Sabalski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1140792A1 publication Critical patent/EP1140792A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Definitions

  • This invention relates to novel N-substituted 3,4-diamino-3-cyclobutene-l,2- dione derivatives which inhibit leukocyte adhesion mediated by interaction of the ⁇ 4 ⁇ . integrin (VLA-4) with its counterreceptor VCAM-1, and their use for the treatment of inflammatory and autoimmune diseases.
  • VLA-4 ⁇ 4 ⁇ . integrin
  • VLA-4 (also referred to as ⁇ ⁇ , integrin and CD49d/CD29), first identified by Hemler and Takada (Hemler and Takada, European Patent Application, Publication No. 330, 506, published August 30, 1989) is a member of the ⁇ , integrin family of cell surface receptors, each of which comprises two subunits, an ⁇ chain and a ⁇ , chain. There are at least nine ⁇ , integrins, all sharing the same ⁇ , chain and each having a distinct ⁇ chain. These nine receptors all bind a different complement of the various cell matrix molecules such as fibronectin, laminin and collagen. VLA-4, for example, binds to fibronectin.
  • VLA-4 is unique among ⁇ , integrins in that it also binds non-matrix molecules that are expressed by endothelial and other cells. These non-matrix molecules include VCAM-1, which is expressed on cytokine-activated human umbilical vein endothelial cells in culture. Distinct epitopes of VLA-4 are responsible for fibronectin and VCAM- 1 binding activities and each activity has been shown to be inhibited independently (Elices, et al, Cell, 60:577-584 (1990)).
  • Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses.
  • activated vascular endothelial cells express molecules that are adhesive for leukocytes.
  • the mechanics of leukocyte adhesion to endothelial cells involves, in part, the recognition and binding of cell surface receptors on leukocytes to the corresponding cell surface molecules on endothelial cells. Once bound, the leukocytes migrate across the blood vessel wall to enter the injured site and release chemical mediators to combat infection.
  • adhesion receptors of the immune system see, for example. Springer (Springer, Nature, 346:425-434 (1990)) and Osborn (Osborn, Cell, 62:3-6 (1990)).
  • Inflammatory brain disorders such as multiple sclerosis (MS) and meningitis
  • MS multiple sclerosis
  • meningitis are examples of central nervous system disorders in which the endothelium / leukocyte adhesion mechanism results in destruction to otherwise healthy brain tissue.
  • BBB blood brain barrier
  • the leukocytes release toxic mediators that cause extensive tissue damage resulting in impaired nerve conduction and paralysis.
  • tissue damage also occurs via an adhesion mechanism resulting in migration or activation of leukocytes.
  • tissue damage also occurs via an adhesion mechanism resulting in migration or activation of leukocytes.
  • an adhesion mechanism mediated by an adhesion mechanism include asthma (Pretolani, et al., J. Exp. Med., 180:795 (1994); Abraham, et al., Clin.
  • each receptor/ligand interaction is rapidly reversible; however, during the process of cell adhesion, multiple ⁇ 4 ⁇ , integrin receptors on one cell engage multiple VCAM-1 ligands on another cell, and together provide a strong and stable adhesive bond.
  • small molecule inhibitors of ⁇ 4 ⁇ ⁇ integrin must achieve a high degree of receptor occupancy for disruption of a significant number of these adhesive interactions.
  • inhibitory compounds exhibit a very steep titration curve, since inhibition begins with 85-90% receptor occupancy and is complete when 95-100% of the receptors are occupied. With such a narrow dynamic range there is considerable assay to assay variation in cell-based adhesion studies.
  • A is alkylene or alkenylene.
  • This invention provides novel compounds of Formula I
  • R 1 is alkyl, aryl. heteroaryl. aralkyl or heteroaralkyl:
  • R 2 is H, alkyl. aryl, heteroaryl, aralkyl, or heteroaralkyl; or R' and R 2 may be taken together to form a saturated or unsaturated heterocycloalkyl;
  • R 3 is H, alkyl. aryl. heteroaryl, aralkyl, or heteroaralkyl;
  • A is aryl or heteroaryl; and
  • x, y and z are independently 0, 1, 2, 3, or a pharmaceutical salt thereof.
  • R 1 is alkyl of 1 to 10 carbon atoms, aralkyl of 7 to 1 1 carbon atoms, or heteroaralkyl of 7 to 1 1 members having 1 to 3 heteroatoms. In still more preferred embodiments of the present invention R 1 is straight chain alkyl of 4 to 8 carbon atoms, benzyl, benzhydryl, phenethyl, pyridylmethyl or pyridylethyl.
  • R 2 is preferably hydrogen, alkyl of 1 to 10 carbon atoms or aralkyl of 7 to 1 1 carbon atoms. More preferably R 2 is hydrogen, alkyl of 1 to 6 carbon atoms, benzyl or naphfhylmethyl. Alternatively, when R 1 and R 2 are taken together, they preferably form a substituted heterocycloalkyl of 5 to 7 members having 1 to 3 heteroatoms selected from N, O and S.
  • A is preferably substituted or unsubstituted aryl.
  • the substituent is preferably selected from -NR 4 COR 5 , -OCONR 6 R 7 or -O(CHdonating)mNR 6 R 7 wherein R 4 is hydrogen or alkyl of 1 to 3 carbon atoms, R " is substituted or unsubstituted aryl, heteroaryl or heterocycloalkyl, R 6 and R 7 are independently, hydrogen or alkyl of 1 to 3 carbon atoms, or R 6 and R 7 , taken together may form a substituted heterocycloalkyl, and m is an integer from 1 to 6. In some embodiments of the present invention it is preferred that x and y are 0 and z is 1.
  • R 3 is preferably hydrogen in some aspects of the invention.
  • preferred substituents are alkyl of 1 to 3 carbon atoms, aryl, -COR * or -COOR 9 wherein R 8 is alkyl of 1 to 3 carbon atoms, aryl of 5 or 6 carbon atoms or aralkyl of 6 or 7 carbon atoms, and R 9 is hydrogen, alkyl of 1 to 3 carbon atoms, aryl of 5 or 6 carbon atoms or aralkyl of 6 or 7 carbon atoms.
  • R 1 is alkyl, aralkyl or heteroaralkyl
  • A is phenyl
  • x and y are 0, and z is 1.
  • More preferred compounds of the present invention are the following compounds:
  • Alkyl' as used herein means a branched or straight chain having from 1 to
  • alkyl groups include methyl, ethyl, propyl. isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
  • Alkyl may be substituted and unsubstituted.
  • Aryl' as used herein means mono or bicyclic aromatic ring having from 5 to
  • Monocyclic rings preferably have 5 or 6 members and bicyclic rings preferably have 8, 9 or 10 membered ring structures.
  • Exemplary aryl groups include phenyl and naphthyl.
  • Aryl may be substituted or unsubstituted.
  • Aralkyl as used herein means an aryl-alkyl group in which the aryl and alkyl group are previously defined. Exemplary aralkyl groups include benzyl and phenethyl. The aralkyl may be substituted or unsubstituted.
  • Halogen is chlorine, fluorine, iodine or bromine.
  • Heteroaryl whether used alone or as part of a group such as “heteroaralkyl' " means 5 to 10 membered mono or bicyclic aromatic ring having from 1 to 3 heteroatoms selected from N. O and S.
  • Exemplary heteroaryls include pyridyl, pyrazinyl, pyridazinyl. pyrimidinyl, indolyl, imidazolyl, pyrazolyl and pyrrolyl.
  • Preferred heteroaryl groups include lH-indoly-3-yl, pyridin-3-yl, pyridin-4-yl, and 1H- imidazol-4-yl.
  • the heteroaryl may be substituted or unsubstituted.
  • Hetcraralkyl means an heteroaryl-alkyl group in which the heteroaryl and alkyl are as previously described.
  • exemplary heteroaralkyls include pyridylmethyl, pyridylethyl. thienylethyl, thienylmethyl. indolylmethyl. and furylmethyl.
  • the heteraralkyl may be substituted or unsubstituted.
  • Heterocycloalkyl refers to a monocycloalkyl having from 5 to 10 members including one or more heteroatoms selected from N, O or S.
  • the heterocycloalkyl may be saturated or unsatured and may be substituted or unsubstituted.
  • Suitable substituents are unsubstituted and include, but are not limited to, alkyl of 1 to 3 carbon atoms, halogen, -CN, -NO 2 , perhaloalkyl of 1 to 3 carbon atoms, aryl. aralkyl, -NR COR 5 , -CO 2 R 4 , -OR 4 , -OCONR 6 R 7 or -O(CH 2 )mNR 6 R 7 wherein R 4 is hydrogen, alkyl of 1 to 3 carbon atoms, or aralkyl of 7-10 carbon atoms, R 5 is aryl.
  • R 6 and R 7 are independently, hydrogen or alkyl of 1 to 3 carbon atoms, or R 6 and R 7 , taken together may form a heterocycloalkyl, and m is an integer from 1 to 6.
  • Carbon number refers to the number of carbons in the carbon backbone and does not include carbon atoms occurring in substituents thereof.
  • Pharmaceutically acceptable salts are the acid addition salts which can be formed from a compound of the above general formula and a pharmaceutically acceptable acid such as phosphoric, sulfuric. hydrochloric, hydrobromic, citric, maleic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid, and the like.
  • a pharmaceutically acceptable acid such as phosphoric, sulfuric. hydrochloric, hydrobromic, citric, maleic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid, and the like.
  • the compounds of this invention contain a chiral center, providing for various seteroisomeric forms of the compounds such as racemic mixtures as well as the individual optical isomers.
  • the individual isomers can be prepared directly or by asymmetric or stercospecific synthesis or by conventional separation of optical isomers from the racemic mixture.
  • Novel compounds of Formula I are prepared by the sequential addition of appropriate amine nucleophilcs to 3.4-diethoxy-3-cyclobutene- 1.2-dione in alcoholic solvent, followed by hydrolysis of the precursor carboxylic acid ester to the parent acid by treatment with aqueous base as shown in the following reaction schemes.
  • Example 8 2-(3.4-Dioxo-2-r(pyridin-3-ylmethyl)-aminol-cvclobut-l-enylamino)-3-phenyl-pro pionic acid methyl ester
  • the lithium salt of the title compound was obtained in 66% yield as a light yellow solid.
  • the modified procedure requires removing the volatiles in vacuo from the reaction mixture following completion of ester hydrolysis (usually 3 hours at room temperature), followed by partitioning the reaction mixture between EtOAc and water. The aqueous phase is then lyophilized to afford the lithium salt as an amorphous powder.
  • Example 36 N-r2-rMethyl(2-phenylethyl)aminol-3.4-dioxo-l -cyclobuten- l-yl]-4-r(4- pyridinylcarbonyl)aminol-L-phenylalanine methyl ester
  • IR (KBr, cm “1 ) 3375 (br), 2900, 1800, 1660, 1575, 1530, 1410, 1325.
  • Example 47 N-12-(Methyl-pyridin-3-ylmethyl-amino)-3.4-dioxo-cvclobut-l-enyl]-4-r(pyridine-3- carbonyl)-aminol-L-phenylalanine methyl ester
  • IR (KBr, cm “1 ) 3410, 2920, 1810, 1730, 1580, 1530, 1410, 1220.
  • VLA-4 binding activity of exemplary compounds was measured by measuring the inhibition of the interaction of soluble VCAM-1 with Jurkat cells (ATCC #TIB-153) which express high levels of ⁇ 4 ⁇ , integrin (VLA-4) using a modification of the fluorescence activated cell sorter (FACS) assay described by Yednock, et al., J. Biol. Chem., 1995, 270:28740.
  • FACS fluorescence activated cell sorter
  • Jurkat cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin, streptomycin and glutamine as described by Yednock, supra.
  • Recombinant soluble VCAM-1 (rsVCAM-1) was produced in a baculovirus expression system as a chimeric fusion protein containing the seven immunoglobulin domains of VCAM-1 on the N-terminus and the human IgG, heavy chain constant region on the C-terminus as described by Yednock, supra. Supernatant containing approximately lOug/ml rs VCAM-1 was collected after 72 hours and used in the assay without purification.
  • Jurkat cells (approximately 10 7 cells/ml) were treated with 1.5mM MnCl 2 and
  • Cells were washed twice and resuspended in 100 ⁇ l of a 1 : 100 dilution of FITC-conjugated goat anti-human IgG to detect the human Ig-VCAM-1 construct diluted in assay media containing 2.5% mouse serum to block potential cross- reactivity with cell surface bound 15/7. Cells were incubated on ice for 30 minutes in the dark. Cells were washed twice and analyzed with a standard FACS analysis as described in Yednock, et al., supra, on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
  • compounds of the present invention exhibit high affinity for VLA-4, and can effectively inhibit the interaction of VLA-4 with VCAM.
  • the compounds are useful for the treatment of inflammatory and autoimmune diseases including, but not limited to multiple sclerosis, meningitis, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel syndrome, rheumatoid arthritis, tumor metastasis, tissue transplantation, and myocardial ischemia.
  • the compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases.
  • These salts include, but are not limited to, salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and salts with organic acids such as acetic acid, oxalic acid, succinic acid, and maleic acid.
  • Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium.
  • the compounds of the present invention can also be used in the form of esters at the C-terminus; carbamates, amides and the like at the N-terminus or other conventional "pro-drug" forms which, when administered, convert to the active moiety in vivo.
  • Compounds of the present invention may be administered in combination with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like.
  • Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils.
  • Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA. These compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes.
  • formulations may contain, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, or elixirs containing, for example, from about 20 to 50% ethanol, and the like.
  • formulation may be, for example, sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium.
  • Such pharmaceutical preparations may contain, for example, from about 25 to about 90% by weight of active ingredient in combination with a carrier, and more preferably between about 5% and 60% by weight of active ingredient.
  • compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
  • the dosage requirements can be determined by one skilled in the art and will vary with the particular composition employed, the route of administration, the severity of the symptoms presented and the particular subject being treated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), dont l'adhérence aux leucocytes a pour origine l'interaction de l'intégrine α4β1 (VLA-4) et de son contre-récepteur VCAM-1. Cette invention concerne également l'utilisation de ces composés pour traiter les maladies inflammatoires et auto-immunes.
EP99967265A 1998-12-14 1999-12-10 Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4 Withdrawn EP1140792A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21118398A 1998-12-14 1998-12-14
US211183 1998-12-14
PCT/US1999/029369 WO2000035855A1 (fr) 1998-12-14 1999-12-10 Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4

Publications (1)

Publication Number Publication Date
EP1140792A1 true EP1140792A1 (fr) 2001-10-10

Family

ID=22785877

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967265A Withdrawn EP1140792A1 (fr) 1998-12-14 1999-12-10 Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4

Country Status (7)

Country Link
EP (1) EP1140792A1 (fr)
JP (1) JP2002532457A (fr)
CN (1) CN1334797A (fr)
AU (1) AU2357600A (fr)
BR (1) BR9916211A (fr)
CA (1) CA2351464A1 (fr)
WO (1) WO2000035855A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (fr) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Derives de phenylalanine en tant qu'inhibiteurs d'integrines alpha 4
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) * 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
EP1244656A1 (fr) 1999-12-28 2002-10-02 Pfizer Products Inc. Inhibiteurs non peptidyle de liaison cellulaire dependant de vla-4 utiles pour le traitement de maladies inflammatoires, auto-immunes et respiratoires
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) * 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) * 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
WO2002004426A1 (fr) * 2000-07-07 2002-01-17 Celltech R & D Limited Derives d'acide squarique contenant un noyau heteroaromatique bicyclique comme antagonistes d'integrine
EP1305291A1 (fr) * 2000-08-02 2003-05-02 Celltech R&D Limited Derives d'isoquinoline-1-yl substitues en 3
FR2815345B1 (fr) * 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) * 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
WO2002051396A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
PL208928B1 (pl) * 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
KR20040093692A (ko) 2002-03-13 2004-11-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
GB0216574D0 (en) * 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
TWI330174B (en) * 2002-07-30 2010-09-11 Schering Corp 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
MY139601A (en) 2002-10-09 2009-10-30 Schering Corp Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CA2550540A1 (fr) 2003-12-22 2005-07-28 Schering Corporation Dioxydes d'isothiazole en tant que ligands du recepteur de la chimiokine cxc et cc
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP1674457B1 (fr) 2004-12-23 2009-06-03 GPC Biotech AG Derives d'acide squarique presentant und activité antiproliferative
JP2009500328A (ja) 2005-06-29 2009-01-08 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドとしての５，６−ジ−置換オキサジアゾロピラジンおよびチアジアゾロピラジン
MX2008000366A (es) 2005-06-29 2008-03-07 Schering Corp Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina.
ES2366132T3 (es) * 2005-10-27 2011-10-17 Janssen Pharmaceutica Nv Derivados del ácido escuárico como inhibidores de la histona desacetilasa.
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
FR2918665B1 (fr) * 2007-07-13 2009-10-02 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25
EP4541422A3 (fr) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311282D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
US6140368A (en) * 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035855A1 *

Also Published As

Publication number Publication date
CA2351464A1 (fr) 2000-06-22
WO2000035855A1 (fr) 2000-06-22
JP2002532457A (ja) 2002-10-02
AU2357600A (en) 2000-07-03
CN1334797A (zh) 2002-02-06
BR9916211A (pt) 2001-09-11

Similar Documents

Publication Publication Date Title
WO2000035855A1 (fr) Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4
US7410984B2 (en) Compounds
US6166050A (en) 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
AU725403B2 (en) Thrombin inhibitors
US6426348B1 (en) Diphenyl heterocyclic thioamide derivatives
US5948785A (en) Heterocyclic amide compounds and pharmaceutical use of the same
US6624152B2 (en) Cell adhesion inhibitors
KR100637110B1 (ko) 세포 유착 억제제
US20030119788A1 (en) Novel compounds and compositions as protease inhibitors
RU2270193C2 (ru) 4-пиридинил-n-ацил-l-фенилаланины
JP2000502702A (ja) 抗ヘルペスウイルス性を有するフェニルチアゾール誘導体
JP2000501090A (ja) アミノ酸誘導体、該化合物含有薬剤およびその製造方法
US20030114490A1 (en) New phenylalanine derivatives
US6545160B2 (en) αaminocetic acid derivatives- α4β7 receptor antagonists
DE19544686A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040053907A1 (en) Cell adhesion inhibitors
EP0636621A1 (fr) Dérivés des propanamid-bêta mercapto utiles dans le traitement des maladies du système cardiovasculaire
MXPA01005968A (en) 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
AU708306B2 (en) Esters and amides as PLA2 inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010523;LT PAYMENT 20010523;LV PAYMENT 20010523;MK;RO PAYMENT 20010523;SI PAYMENT 20010523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030828